VIR at a discount
Updated
VIR has a couple of interesting products testing in the pipeline.
The one that caused the spike in Jan is for hepatitis B treatment.
And the selloff today is caused by the pause in the enrollment of late-stage trial testing of their Covid19 antibody.
So it seems it is safe to assume that it will return above previous resistance of 53. With 80's as a first target, and then, potentially, to ATH.
The one that caused the spike in Jan is for hepatitis B treatment.
And the selloff today is caused by the pause in the enrollment of late-stage trial testing of their Covid19 antibody.
So it seems it is safe to assume that it will return above previous resistance of 53. With 80's as a first target, and then, potentially, to ATH.
Note
Nice opening todayNot taking profit, expecting higher
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.